<h4>Background</h4>A Japanese phase 2 trial of encorafenib plus binimetinib met the primary endpoint of the centrally assessed objective response rate in patients with unresectable BRAF V600E-mutated thyroid cancer. Here, BRAF is linked to thyroid gland carcinoma.